64695-96-1

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-5-fluoro-2-methyl-4-nitrobenzene is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be modified and incorporated into complex molecular structures, contributing to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Bromo-5-fluoro-2-methyl-4-nitrobenzene serves as a key intermediate in the production of agrochemicals, such as pesticides and herbicides, due to its potential to be transformed into active ingredients with targeted biological activities.
Used in Organic Synthesis:
As a halogenated aromatic compound, 1-Bromo-5-fluoro-2-methyl-4-nitrobenzene is utilized as a building block in organic synthesis for the creation of a wide range of chemical products, including specialty chemicals and advanced materials.
Safety and Environmental Considerations:
It is crucial to handle 1-Bromo-5-fluoro-2-methyl-4-nitrobenzene with care, as it may pose health and environmental risks if not properly managed. Appropriate safety measures should be taken during its production, use, and disposal to minimize potential hazards.

InChI:InChI=1S/C7H5BrFNO2/c1-4-2-7(10(11)12)6(9)3-5(4)8/h2-3H,1H3

Upstream product

• 1422-53-3 2-bromo-4-fluorotoluene 

Relevant academic research and scientific papers

ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.

Ceritinib intermediate and preparation method and application thereof

The present invention discloses a ceritinib intermediate and a preparation method and application thereof. The ceritinib intermediate has a structure shown as a formula I, R and R2 are as defined in the specification and claims. The ceritinib intermediate is prepared from a compound of a formula 1 and a benzyl halide compound by substitution reaction and then reduction. After further reduction of the nitro by catalytic hydrogenation and removal of amino-protection, the compound of the formula I is reacted with a compound of a formula III to obtain ceritinib. According to the method, raw materials are readily available and inexpensive, the method does not require special equipment, production cost is greatly reduced, and the method is suitable for industrial application.

PROCESS FOR PREPARATION OF CERITINIB

The present application relates to a process for preparation of ceritinib and intermediates thereof. Specifically, the present application relates to a process for preparation of N-(4-(1-benzyl- 1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)acetamide (VC) comprising treating N-(4-(bromomethyl)-2-isopropoxy-5-methylphenyl)acetamide (IIID) with 1- benzylpiperidin-4-one (IVA). The present application also relates to a process for conversion of N-(4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-acetamide (VC) to ceritinib or an acid-addition salt thereof.

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

The present invention aims to provide a drug for the treatment or prophylaxis of pathology in general in which SNS is involved, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The present inventi